0000000000343263

AUTHOR

Maria Felicia Faienza

showing 5 related works from this author

Cardiovascular dysfunction and vitamin D status in childhood acute lymphoblastic leukemia survivors

2018

Vitamin D (25-OHD) has a role in bone health after treatment for cancer. 25-OHD deficiency has been associated with risk factors for cardiovascular disease, but no data focusing on this topic in childhood cancer survivors have been published. We investigated the 25-OHD status in children treated for acute lymphoblastic leukemia (ALL), and evaluated its influence on vascular function. 25-OHD levels were evaluated in 52 ALL survivors and 40 matched healthy controls. Patients were grouped according to 25-OHD level (< 20 ng/m or ≥ 20 ng/ml). Auxological parameters, biochemical and hemostatic markers of endothelial function (AD, HMW-AD, ET-1, vWFAg, TAT, D-dimers, Fbg, and hs-CRP), ultrasound ma…

Malemedicine.medical_specialtyendocrine system diseasesAdolescentDiseaseAcute lymphoblastic leukemiaurologic and male genital diseasesGastroenterologyC-IMT03 medical and health sciencesYoung Adult0302 clinical medicineRisk Factors030225 pediatricsmedicine.arteryInternal medicinePediatric surgerymedicineVitamin D and neurologyHumans030212 general & internal medicineSurvivorsVitamin DChildChildhood Acute Lymphoblastic LeukemiaUnivariate analysisbusiness.industryAbdominal aortaConfoundingnutritional and metabolic diseasesCancerPrecursor Cell Lymphoblastic Leukemia-Lymphomamedicine.diseaseVitamin D DeficiencyCardiovascular diseaseChild PreschoolPediatrics Perinatology and Child HealthFemaleEndothelium VascularbusinessBiomarkersVascular ultrasound studie
researchProduct

Assessment of Cardiovascular Function in Childhood Leukemia Survivors: The Role of the Right Heart

2022

Childhood acute lymphoblastic leukemia (ALL) survivors who underwent chemotherapy with anthracyclines have an increased cardiovascular risk. The aim of the study was to evaluate left and right cardiac chamber performances and vascular endothelial function in childhood ALL survivors. Fifty-four ALL survivors and 37 healthy controls were enrolled. All patients underwent auxological evaluation, blood pressure measurements, biochemical parameters of endothelial dysfunction, flow-mediated dilatation (FMD) of the brachial artery, mean common carotid intima-media thickness (c-IMT), antero-posterior diameter of the infra-renal abdominal aorta (APAO), and echocardiographic assessment. The ALL subjec…

vascular toxicitycardiac function; childhood; acute lymphoblastic leukemia; vascular toxicityPediatrics Perinatology and Child Healthacute lymphoblastic leukemiacardiac functionchildhoodChildren
researchProduct

17β-Hydroxysteroid dehydrogenase-3 deficiency: From pregnancy to adolescence

2009

OBJECTIVE: Aim of this study is to report on basal clinical phenotype and follow up after diagnosis, of patients with 17beta-hydroxysteroid-dehydrogenase type 3 (17beta-HSD3) deficiency in Italy. SETTING: Pediatric Endocrine Departments, University Hospitals. PATIENTS: The cases of 5 Italian subjects affected by 17beta-HSD3 deficiency are presented in this study. INTERVENTIONS: Laboratory and genetic assessment. Gonadectomy and female sex assignment (4 patients) or GnRH analog therapy to regress puberty and gender identity disorder (1 patient). RESULTS: Presentation lasted from pregnancy (pre-natal diagnosis of a 46,XY fetus with female external genitalia) to infancy (inguinal hernia contai…

MaleGender Identity DisorderPediatricsmedicine.medical_specialty17-Hydroxysteroid DehydrogenasesEndocrinology Diabetes and MetabolismSex assignmentPrenatal diagnosisGene mutationBiologyClitoromegalyAdolescence pregnancy 17beta-Hydroxysteroid dehydrogenase-3 deficiencySettore MED/38 - Pediatria Generale E SpecialisticaEndocrinologyPregnancyPrenatal DiagnosismedicineHumansDisorders of sex developmentDISORDERS OF SEX DEVELOPMENTTestosterone17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 GENEGynecologyPregnancyPubertymedicine.diseaseFemaleMALE/FEMALE SEX REVERSALTESTOSTERONE/D4-ANDROSTENEDIONE RATIO17-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 3 DEFICIENCYmedicine.symptomJournal of Endocrinological Investigation
researchProduct

MODELLO DI PREVISIONE DELLA STATURA FINALE IN PAZIENTI PEDIATRICI ITALIANI AFFETTI DA DEFICIT DI GH TRATTATI CON SOMATROPINA

2021

Obiettivi: elaborare un modello di previsione della statura finale in pazienti pediatrici con deficit di GH trattati con somatropina ricombinante, valutando quali siano le variabili più importanti nel determinismo della statura finale. Metodi: 1043 pazienti trattati per deficit di GH (picco di GH &lt;10 ng/dl a 2 test di stimolo) giunti ad altezza finale. Mediana età a inizio trattamento 11 (IQR 8.7/12.8) anni; mediana altezza a inizio trattamento -2.43 (IQR -2.80/-2.01) SDS; mediana altezza bersaglio -1.09 (IQR -1.63/-0.48) SDS; dose iniziale di somatropina mediana altezza finale -1.08 SDS (IQR -1.64/-0.50 SDS, vs altezza a inizio trattamento p &lt;0.001, vs altezza bersaglio p=ns). Analis…

Settore MED/38 - Pediatria Generale E SpecialisticaMODELLO DI PREVISIONE STATURA FINALE DEFICIT DI GHSOMATROPINA
researchProduct

Isolated childhood growth hormone deficiency: a 30-year experience on final height and a new prediction model

2022

Purpose We aimed to evaluate the near-final height (nFHt) in a large cohort of pediatricpatients with growth hormone deficiency (GHD) and to elaborate a new predictive method of nFHt. Methods We recruited GHD patients diagnosed between 1987 and 2014 and followed-up until nFHt. To predict the values of nFHt, each predictor was run in a univariable spline. Results We enrolled 1051 patients. Pre-treatment height was -2.43 SDS, lower than parental height (THt) (-1.09 SDS, p &lt; 0.001). The dose of recombinant human GH (rhGH) was 0.21mg/kg/week at start of treatment. nFHt was -1.08 SDS (height gain 1.27 SDS), higher than pre-treatment height (p &lt; 0.001) and comparable to THt. 1.6% of the pat…

Insulin-like growth factor 1Human Growth HormoneEndocrinology Diabetes and MetabolismPubertyFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; PredictionDwarfismGrowthBody HeightCohort StudiesEndocrinologySettore MED/38 - Pediatria Generale E SpecialisticaGrowth hormone retestingPituitaryFinal heightGrowth HormoneFinal height; Growth; Growth hormone deficiency; Growth hormone retesting; Insulin-like growth factor 1; LMG method; Prediction; Body Height; Child; Cohort Studies; Growth Hormone; Humans; Puberty; Dwarfism Pituitary; Human Growth HormoneHumansGrowth hormone deficiencyLMG methodDwarfism PituitaryPredictionChildFinal height Growth Growth hormone deficiency Growth hormone retesting Insulin-like growth factor 1 LMG method Prediction
researchProduct